1,4-Dihydroxy-2,3-dioxatricyclo[8.4.0.0(4,9)]tetradecane and derivatives with in vitro activity against Plasmodium falciparum, Trypanasoma b brucei, Trypanasoma cruzi, and Leishmaniasis infantum.
1,4-Dihydroxy-2,3-dioxatricyclo[8.4.0.0(4,9)]tetradecane and derivatives have been synthesised and their in vitro activity against Plasmodium falciparum (malaria) Ghana, Trypanasoma b brucei (sleeping sickness) TB-1, and Trypanasoma cruzi (Chagas' disease) TC-1, and Leishmaniasis infantum (leishmaniasis) L1 parasite strains has been assessed.
Howarth
Joshua
J
School of Chemical Sciences, Dublin City University, Glasnevin, Dublin, 9, Ireland. joshua.howarth@dcu.ie
Wilson
Darragh
D
D000473:Alkanes / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D000981:Antiprotozoal Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000737:chemistry / Q000494:pharmacology; D002460:Cell Line; D006801:Humans; D020128:Inhibitory Concentration 50; D018314:Leishmania infantum / Q000187:drug effects*; D010963:Plasmodium falciparum / Q000187:drug effects*; D013329:Structure-Activity Relationship; D014346:Trypanosoma brucei brucei / Q000187:drug effects*; D014349:Trypanosoma cruzi / Q000187:drug effects*
D000473:Alkanes; D000981:Antiprotozoal Agents; D001952:Bridged-Ring Compounds